SG11201910043PA - Manufacture of trans-[tetrachlorobis(1h-indazole)ruthenate (iii)] and compositions thereof - Google Patents
Manufacture of trans-[tetrachlorobis(1h-indazole)ruthenate (iii)] and compositions thereofInfo
- Publication number
- SG11201910043PA SG11201910043PA SG11201910043PA SG11201910043PA SG 11201910043P A SG11201910043P A SG 11201910043PA SG 11201910043P A SG11201910043P A SG 11201910043PA SG 11201910043P A SG11201910043P A SG 11201910043PA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- compositions
- tetrachlorobis
- ruthenate
- tampa
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
- C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
- C07F15/0046—Ruthenium compounds
- C07F15/0053—Ruthenium compounds without a metal-carbon linkage
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762501984P | 2017-05-05 | 2017-05-05 | |
| PCT/US2018/031436 WO2018204930A1 (en) | 2017-05-05 | 2018-05-07 | Manufacture of trans-[tetrachlorobis(1h-indazole)ruthenate (iii)] and compositions thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201910043PA true SG11201910043PA (en) | 2019-11-28 |
Family
ID=64016742
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201910043P SG11201910043PA (en) | 2017-05-05 | 2018-05-07 | Manufacture of trans-[tetrachlorobis(1h-indazole)ruthenate (iii)] and compositions thereof |
Country Status (11)
| Country | Link |
|---|---|
| US (5) | US10611787B2 (enExample) |
| EP (3) | EP3618827B1 (enExample) |
| JP (4) | JP7183253B2 (enExample) |
| CN (2) | CN117462558A (enExample) |
| AU (2) | AU2018263965B2 (enExample) |
| CA (1) | CA3062369A1 (enExample) |
| ES (1) | ES2959891T3 (enExample) |
| PL (1) | PL3618827T3 (enExample) |
| RU (1) | RU2019138773A (enExample) |
| SG (1) | SG11201910043PA (enExample) |
| WO (1) | WO2018204930A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3618827B1 (en) * | 2017-05-05 | 2023-07-26 | Bold Therapeutics Inc. | Manufacture of trans-[tetrachlorobis(1h-indazole)ruthenate (iii)]and compositions thereof |
| US20230024119A1 (en) * | 2019-12-05 | 2023-01-26 | Bold Therapeutics, Inc. | Combined use of sodium trans-[tetrachloridobis(1h-indazole)ruthenate(iii)] and etomoxir for treating cancers |
| WO2021195763A1 (en) * | 2020-03-30 | 2021-10-07 | Bold Therapeutics Inc. | Antiviral ruthenate(iii) therapeutics |
| EP4247413A4 (en) * | 2020-11-18 | 2024-10-09 | Bold Therapeutics Inc. | USE OF SODIUM TRANS-[TETRACHLORIDOBIS(1H-INDAZOLE)RUTHENATE(III)] FOR THE TREATMENT OF CANCERS |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19612291A1 (de) * | 1996-03-28 | 1997-10-02 | Bernhard K Prof Dr Dr Keppler | Arzneimittelzubereitungen enthaltend tumorhemmend wirkende Ruthenium(III)-Komplexe |
| DE10103565B4 (de) * | 2001-01-26 | 2007-06-14 | Faustus Forschungs Cie. Translational Cancer Research Gmbh | Zusammensetzungen, enthaltend einen Ruthenium(III)-komplex und einen Heterocyclus |
| ES2441262T3 (es) | 2007-06-11 | 2014-02-03 | Niiki Pharma Inc. | Método de fabricación de un complejo de rutenio |
| EP2509599B1 (en) * | 2009-12-11 | 2014-08-13 | Niiki Pharma Inc. | Method for treating pancreatic cancer |
| JP5826259B2 (ja) | 2010-06-22 | 2015-12-02 | フイルメニツヒ ソシエテ アノニムＦｉｒｍｅｎｉｃｈ Ｓａ | ルテニウムベース錯体 |
| WO2012012305A2 (en) | 2010-07-18 | 2012-01-26 | Niiki Pharma Inc. | Combination therapy using a ruthenium complex |
| US10766915B2 (en) | 2013-03-15 | 2020-09-08 | Sherri Ann McFARLAND | Metal-based coordination complexes as photodynamic compounds and their use |
| CN103601759B (zh) | 2013-10-18 | 2015-08-19 | 武汉利宝瑞医药科技有限公司 | 一种用于治疗肿瘤的钌(iii)络合物的制备方法 |
| US10342801B2 (en) * | 2015-06-23 | 2019-07-09 | Placon Therapeutics, Inc. | Platinum compounds, compositions, and uses thereof |
| EP3618827B1 (en) * | 2017-05-05 | 2023-07-26 | Bold Therapeutics Inc. | Manufacture of trans-[tetrachlorobis(1h-indazole)ruthenate (iii)]and compositions thereof |
-
2018
- 2018-05-07 EP EP18794220.6A patent/EP3618827B1/en active Active
- 2018-05-07 JP JP2020511873A patent/JP7183253B2/ja active Active
- 2018-05-07 SG SG11201910043P patent/SG11201910043PA/en unknown
- 2018-05-07 WO PCT/US2018/031436 patent/WO2018204930A1/en not_active Ceased
- 2018-05-07 CN CN202311350513.0A patent/CN117462558A/zh active Pending
- 2018-05-07 CN CN201880043453.9A patent/CN111372939B/zh active Active
- 2018-05-07 EP EP23186755.7A patent/EP4245305B1/en active Active
- 2018-05-07 US US15/973,370 patent/US10611787B2/en active Active
- 2018-05-07 EP EP25200214.2A patent/EP4635503A3/en active Pending
- 2018-05-07 ES ES18794220T patent/ES2959891T3/es active Active
- 2018-05-07 RU RU2019138773A patent/RU2019138773A/ru unknown
- 2018-05-07 AU AU2018263965A patent/AU2018263965B2/en active Active
- 2018-05-07 PL PL18794220.6T patent/PL3618827T3/pl unknown
- 2018-05-07 CA CA3062369A patent/CA3062369A1/en active Pending
-
2020
- 2020-02-04 US US16/781,060 patent/US11040993B2/en active Active
-
2021
- 2021-05-26 US US17/330,822 patent/US11739111B2/en active Active
-
2022
- 2022-11-22 JP JP2022186393A patent/JP7433402B2/ja active Active
-
2023
- 2023-07-20 US US18/355,945 patent/US12415825B2/en active Active
-
2024
- 2024-02-06 JP JP2024016340A patent/JP7698083B2/ja active Active
- 2024-05-27 AU AU2024203511A patent/AU2024203511B2/en active Active
-
2025
- 2025-06-12 JP JP2025098540A patent/JP2025123344A/ja active Pending
- 2025-07-23 US US19/277,690 patent/US20260042792A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201809499UA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
| SG11201811150WA (en) | Ev-mediated delivery of binding protein-small molecule conjugates | |
| SG11201908670SA (en) | Pyrrolopyrrole compositions as pyruvate kinase (pkr) activators | |
| SG11201909825VA (en) | Hsp90 inhibitor oral formulations and related methods | |
| SG11201809751XA (en) | Egfr inhibitor compounds | |
| SG11201806544XA (en) | Compounds and methods of treating rna-mediated diseases | |
| SG11201803920TA (en) | Compounds and compositions useful for treating disorders related to ntrk | |
| SG11201907435PA (en) | Combinations of a 4-pyrimidinesulfamide derivative with active ingredients for the treatment of endothelin related diseases | |
| SG11201808108XA (en) | Synthesis of indazoles | |
| SG11201908517XA (en) | Pyrimidinyl-pyridyloxy-naphthyl compounds and methods of treating ire1-related diseases and disorders | |
| SG11201811559WA (en) | Cancer treatment combinations | |
| SG11201900238UA (en) | Compounds and methods for modulation of smn2 | |
| SG11202000333UA (en) | Bicyclic ketone compounds and methods of use thereof | |
| SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201805149XA (en) | Compositions comprising 15-hepe and methods of using the same | |
| SG11201808686VA (en) | Synthesis of indazoles | |
| SG11201908691PA (en) | Compounds and methods for the treatment of parasitic diseases | |
| SG11201901986SA (en) | Process for the manufacture of a solid pharmaceutical adminstration form | |
| SG11201908114UA (en) | Pyrimidopyrimidinones useful as wee-1 kinase inhibitors | |
| SG11201903326RA (en) | Liposomal formulation for use in the treatment of cancer | |
| SG11201809031XA (en) | Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility and cognitive function | |
| SG11201809708PA (en) | Physiologically balanced injectable formulations of fosnetupitant | |
| SG11201804587QA (en) | Isoindole compounds | |
| SG11201906511SA (en) | Compounds and their use in the treatment of schistosomiasis | |
| SG11201806157WA (en) | Method and pharmaceutical composition for treatment of neurodegeneration |